JPMorgan Chase & Co. Has $80.12 Million Position in ICU Medical, Inc. (ICUI)

JPMorgan Chase & Co. boosted its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 432,281 shares of the medical instruments supplier’s stock after buying an additional 14,537 shares during the quarter. JPMorgan Chase & Co. owned 2.16% of ICU Medical worth $80,122,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. BlackRock Inc. raised its position in ICU Medical by 0.6% in the 2nd quarter. BlackRock Inc. now owns 1,780,976 shares of the medical instruments supplier’s stock worth $307,218,000 after buying an additional 11,046 shares during the last quarter. Janus Henderson Group PLC purchased a new position in ICU Medical in the 2nd quarter worth about $247,072,000. Vanguard Group Inc. raised its position in ICU Medical by 16.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,304,282 shares of the medical instruments supplier’s stock worth $224,989,000 after buying an additional 183,133 shares during the last quarter. Wells Fargo & Company MN raised its position in ICU Medical by 19.3% in the 2nd quarter. Wells Fargo & Company MN now owns 555,712 shares of the medical instruments supplier’s stock worth $95,861,000 after buying an additional 89,872 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in ICU Medical by 3.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 388,473 shares of the medical instruments supplier’s stock worth $67,012,000 after buying an additional 14,270 shares during the last quarter. 78.15% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on the company. Gabelli reissued a “buy” rating on shares of ICU Medical in a research report on Friday, August 11th. BidaskClub lowered ICU Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of ICU Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, KeyCorp assumed coverage on shares of ICU Medical in a research report on Tuesday, October 17th. They set a “sector weight” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. ICU Medical has an average rating of “Hold” and an average target price of $232.00.

In related news, VP Virginia Ruth Sanzone sold 1,784 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $174.47, for a total value of $311,254.48. Following the completion of the sale, the vice president now directly owns 102 shares of the company’s stock, valued at approximately $17,795.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert S. Swinney sold 1,000 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $215.10, for a total transaction of $215,100.00. Following the completion of the sale, the director now directly owns 13,330 shares of the company’s stock, valued at $2,867,283. The disclosure for this sale can be found here. Insiders sold a total of 121,447 shares of company stock valued at $23,198,692 over the last three months. 13.60% of the stock is currently owned by insiders.

Shares of ICU Medical, Inc. (NASDAQ ICUI) opened at $203.15 on Wednesday. ICU Medical, Inc. has a 52-week low of $127.00 and a 52-week high of $218.45. The company has a market cap of $4,090.00, a PE ratio of 82.80, a PEG ratio of 3.39 and a beta of 0.36. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.35. ICU Medical had a net margin of 2.79% and a return on equity of 4.81%. The firm had revenue of $343.20 million during the quarter, compared to analyst estimates of $328.56 million. During the same quarter in the prior year, the firm earned $1.35 EPS. The business’s revenue for the quarter was up 253.5% compared to the same quarter last year. sell-side analysts expect that ICU Medical, Inc. will post 3.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/06/jpmorgan-chase-co-has-80-12-million-position-in-icu-medical-inc-icui.html.

ICU Medical Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply